ArticleCell reports methods2025
Fast and sensitive detection of targeted gene fusions using frequency minimizers and fuzzy pattern matching with Fuzzion2.
Article in Cell reports methods, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The landscape of structural variation in pediatric cancer.Cancer cell · 2026Article
- CanID: A Robust and Accurate RNA-seq Expression-based Diagnostic Classification Scheme for Pediatric Malignancies.Genomics, proteomics & bioinformatics · 2025Article
- Sustainable Community-Wide Model to Enhance Cancer Data Usage and Utility.JCO clinical cancer informaticsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
To enable fast and sensitive fusion detection critical for clinical oncology testing, we developed Fuzzion2, a pattern-matching program for detecting targeted gene fusions that employs an index of frequency minimizers and fuzzy matching to accommodate sequence variations. Running against 21,736 reference patterns representing chimeric fusions or internal tandem duplications, Fuzzion2 can analyze an unmapped RNA sequencing (RNA-seq) sample in minutes, at a sensitivity exceeding state-of-the art de novo fusion detection methods as demonstrated by dilution experiments. A comprehensive analysis on 23,478 RNA-seq samples from pediatric cancer, adult cancer, and normal tissues showed cancer type specificity for non-kinase fusions after accounting for multi-tissue recurrences caused by readthrough transcription, germline structural variations, index hopping, and circular RNA expression. Application of Fuzzion2 revealed distinct landscapes of pediatric and adult cancers, and its curated fusion patterns can inform interpretation of fusions detected by other methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.